Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Genetic Testing Market Size to Surge to USD 62.61 Billion by 2035 – SNS Insider

globenewswire.com
ILMN Mentioned as a major company in the genetic testing market, which is projected to grow significantly. The article does not provide specific sentiment towards Illumina itself. MYGN Listed as a major company in the growing genetic testing market. The article does not offer specific positive or negative commentary on Myriad Genetics. TMO Identified as a major player in the genetic testing market, which is expected to experience substantial growth. No specific sentiment is expressed for Thermo Fisher Scientific. NTRA Included as a major company within the expanding genetic testing sector. The article does not provide any explicit sentiment regarding Natera's performance or outlook. GH Mentioned as a key company in the genetic testing market, which is poised for significant expansion. The article does not offer specific sentiment for Guardant Health. INV Named as a major company in the genetic testing industry, which is expected to see considerable growth. No specific sentiment is attributed to Invitae in the article. ABT Listed as a major company in the genetic testing market. The article does not provide specific sentiment for Abbott Laboratories, but its inclusion suggests relevance to the growing market. DGX Listed as a major company in the genetic testing market, which is expected to expand significantly. The article does not provide specific sentiment for Quest Diagnostics. LH Mentioned as a major company in the genetic testing market, which is projected for substantial growth. The article does not offer specific sentiment for LabCorp. CLRS Named as a major company in the genetic testing market, which is expected to grow significantly. The article does not express specific sentiment for Color Genomics.

Genetic Testing Market Size to Surge to USD 62.61 Billion by 2035 – SNS Insider Austin, Texas, Aug. 28, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, the Genetic Testing Market Size was valued at USD 21.67 billion in 2025 and is projected to reach USD 62.61 billion by 2035, expanding at a CAGR of 11.34% from 2026 to 2035. Reduction in sequencing cost, increasing use of genomics in clinical practice, and increased interest in personalized medicine are leading to the expansion of genetic testing from research-oriented to applications in oncology, reproduction, preventive medicine, pharmacogenomics, and consumer genomics.

The following technologies such as next-generation sequencing (NGS), whole genome sequencing, whole exome sequencing, liquid biopsy, genomic analysis aided by artificial intelligence and direct-to-consumer genomics testing are making the market grow. Genetics is becoming more and more widely used in screening, diagnosing, treatment, and even care.

Request a Sample of the Genetic Testing Market Report: https://www.snsinsider.com/sample-request/5721

Key Genetic Testing Market Highlights

Genetic Testing Market Growth Drivers

Genetic testing is gradually becoming an integral part of precision medicine due to the utilization of genomic data by healthcare professionals for predicting disease risk, managing cancers, planning for reproduction, and facilitating optimal therapeutic decisions. The technology of NGS is integral to hereditary disease testing, cancer profiling, pharmacogenomics, carrier screening, and non-invasive prenatal tests.

Another promising area that may become the focus of innovation and development is liquid biopsy since it uses circulating tumor DNA for detecting cancers, treatment monitoring, and assessing the minimal residual disease. In addition to this, genomics is being interpreted with the help of artificial intelligence (AI), thus making possible the analysis of complicated datasets.

Consumer adoption is expanding through home-collection kits, digital result delivery, and telehealth-supported genetic counseling. This creates growth opportunities across both clinical testing and consumer-facing genetic testing services.

Genetic Testing Market Segment Analysis

By Channel: Offline sales contributed about 60.32% to the total income of Genetic Testing Market in 2025 due to the high demand for genetic tests in hospitals and diagnostic labs. Online sales will grow at an annual rate of 12.07% CAGR due to increasing consumer interest in at-home genetic testing.

By Technology: Market Share of Next-Generation Sequencing was around 49.15% in 2025. The application of NGS technology in areas of oncology, genetics, prenatal tests, and pharmacogenomics further increases the need for NGS-based tests.

By Product: Consumables led the market in 2025 as recurring demand for reagents, assay kits, and other testing inputs increased with testing volumes. Equipment and software & services are also expanding as laboratories scale sequencing capacity and genomic data analysis.

By Application: Health & Wellness – Predisposition/Risk represented approximately 51.23% of revenue in 2025. Genetic Disease Carrier Status is expected to be the fastest-growing application, supported by expanded carrier screening in preconception and prenatal care.

By End Use: Hospitals & Clinics dominated in 2025, while diagnostic laboratories continue to benefit from rising clinical test volumes and broader adoption of advanced molecular diagnostics.

Buy the Genetic Testing Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/5721

Regional Genetic Testing Market Outlook

North America was the leading region in the market due to its developed genomic testing landscape, high oncology testing demand, research spendings, and consumer uptake. The U.S. generated around 88% of the total revenues in North America.

The U.S. Genetic Testing Market was valued at USD 6.48 billion in 2025 and is forecast to reach USD 16.92 billion by 2035, growing at a CAGR of 10.08%.

The Europe Genetic Testing Market was valued at USD 6.50 billion in 2025 and is projected to reach USD 18.78 billion by 2035 at a CAGR of 10.90%. Germany accounted for approximately 25% of European revenue, while the UK, France, and Nordic countries remain important genomic medicine markets.

Asia Pacific is expected to be the fastest-growing region. China accounted for approximately 45% of regional revenue, supported by genomic medicine programs, prenatal genetic testing, oncology profiling, and biotechnology infrastructure. Japan and South Korea also contribute through established precision medicine initiatives.

In Middle East & Africa, Israel accounted for approximately 35% of regional revenue. In Latin America, Brazil accounted for approximately 48%, supported by pharmaceutical research, academic genomics, and clinical testing demand.

Competitive Landscape and Business Opportunities

Competition in the Genetic Testing Market is increasingly shaped by sequencing cost, clinical validation, turnaround time, test accessibility, regulatory pathways, AI-assisted interpretation, and integration with personalized medicine workflows.

High-growth opportunities include pharmacogenomics, liquid biopsy, carrier screening, AI-based genomic analysis, and routine clinical use of whole genome and whole exome sequencing.

Major companies include Illumina, Myriad Genetics, Thermo Fisher Scientific, Natera, Guardant Health, Foundation Medicine, Invitae, 23andMe, Abbott Laboratories, Bio-Rad Laboratories, Roche, Quest Diagnostics, LabCorp, GeneDx, Color Genomics, AncestryDNA, Centogene, and Blueprint Genetics.

Explore the Complete Genetic Testing Market Report: https://www.snsinsider.com/reports/genetic-testing-market-5721